Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC

Non-small cell lung cancer (NSCLC) constitutes the majority of the lung cancer population and the prognosis is poor. In recent years, immunotherapy has become the standard of care for advanced NSCLC patients as numerous trials demonstrated that immune checkpoint inhibitors (ICI) are more efficacious...

Descripción completa

Detalles Bibliográficos
Autores principales: Goh, Kah Yee, Cheng, Terence You De, Tham, Su Chin, Lim, Darren Wan-Teck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953588/
https://www.ncbi.nlm.nih.gov/pubmed/36831044
http://dx.doi.org/10.3390/biomedicines11020508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953588/
https://www.ncbi.nlm.nih.gov/pubmed/36831044
http://dx.doi.org/10.3390/biomedicines11020508

Ejemplares similares